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Introduction
Among malignancies, breast cancer has the highest morbidity rates and is the leading cause of cancer death in females worldwide. 1 Metastasis is the major features of malignant tumors and lead to a poor prognosis of patients. And the aggressive ability of malignant cells is the vital parameters of the metastatic cascade. 2 Thus, it's important for us to explore mechanisms that result in the incidence of breast cancer metastasis and detect some prognosis and metastasis associated factors of breast cancer.
The mouse breast cancer 4T1 cells were highly tumorigenic and invasive, inoculation of 4T1 cells in the mammary pad of Balb/c mice produced primary tumors and could spontaneously metastasize to multiple distant organs, with the disease progression similar to human breast cancer. 3, 4 In our study, 4T1 cells were cultured in low density and we observed two kinds of phenotype: sphere-shaped clone (SC) and non-sphere-shaped clone (NSC). Additionally, SC was different from NSC in plenty of aspects like the metastasis competence, metabolic rate, growth rate. Balb/c female mice were used to investigate the metastatic ability SCs and NSCs. The results showed that SC had high metastasis ability. In order to investigate the intrinsic different of SCs and NSCs, we performed mRNA-seq analysis of SCs and NSCs. With the assistance of some bioinformatics web tools (GSEA, Kaplan-Meier (KM) plotter database, the Human Protein Atlas and UALCAN), we found that overexpression of TMED2 was an unfavorable prognostic factor in patients with breast cancer. Members of the transmembrane emp24 domain (Tmed)/p24 family of proteins were needed for the transport of proteins between the Golgi and the endoplasmic reticulum. TMED2 was one member of this family and its function during placental development in mice and normal development of the labyrinth layer had been reported. 5 However, the role of TMED2 in the development of tumorigenesis had been rarely reported. Some reports had pointed out that TMED2 could promote the growth of epithelial ovarian cancer and TMED2 expressed in all gestational stages of human placentas and in choriocarcinoma cell lines. 5, 6 The role of TMED2 in breast cancer remains poorly understood.
Materials and methods

Cell culture
Murine breast cancer 4T1 cell line was obtained from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai). And the cell line used for the experiments was authenticated by SNP analysis within 6 months of receipt. The 4T1 cells were cultivated in complete RPMI-1640 (Life Technologies) with 10% FBS, 100 U/ml penicillin/streptomycin and 2 mM L-glutamine.
Sphere clone (SC) and nonsphere clone (NSC)
In vitro: 4T1 cells were trypinized and resuspended in culture medium at the concentration of 5 cells/ml, then 200 µl cell suspension was added into each well of 96-well plate at the average density of 1 cell/well. After standing for 6 hrs, the plate was placed under an inverted phase contrast microscope to observe the wells containing individual cells and well containing individual cell was marked. After 2 weeks of culture, the wells were observed under the microscope. The well containing a single colony of SC or NSC were counted. SC and NSC were separated for further study.
In vivo: in situ tumors produced by subcutaneous injection of 4T1 cells were removed from mice and prepared into suspensions in culture medium at the concentration of 5 cells/ml, then 200 µl cell suspension was added into each well of 96-well plate at the average density of 1 cell/well. After standing for 6 hrs, the plate was placed under an inverted phase contrast microscope to observe the wells containing individual cells and well containing individual cell was marked. After 2 weeks of culture, the wells were observed under the microscope. The well containing a single colony of SC or NSC were counted.
Immunofluorescent confocal laser microscopy
4T1 cells, NSCs had grown on coverslip and SCs centrifuged onto glass slides and then fixed with 3.7% paraformaldehyde for 15 min. Then 0.2% Triton X-100 was used to permeabilize cells for 15 min at room temperature. The cells were blocked with 3% BSA for 1 hr and incubated with CD44 antibody (1:100 dilution of ab119863, Abcam, UK), CD24 antibody (1:100  dilution )×0.5, where L and W mean mid-axis length and width, respectively. On the day of sacrifice, pulmonary metastasis was assessed by counting the macroscopic metastatic nodules according to our previous report. 9 All the metastasis related organs (lung specimens, heart and bone) were embedded in paraffin. For bone metastasis evaluation, leg bones (femora and tibiae) were decalcified with a decalcifying solution (BOSTER AR1071) for 20 days and embedded in paraffin. The incidence of bone metastasis was evaluated by the visible osteolysis or metastasis foci. Sections stained with H&E were evaluated and photographed.
Preparation of RNA for gene arrays
Three batches (each batch contained 10 clones) of SCs and NSCs from 3 independent experiments were collected. Total RNA was extracted by using the RNeasy kit (Qiagen, Germany) and the quality of the total RNA was checked with the BioAnalyzer (Agilent, Santa Clara, CA, USA).
Transcriptome sequencing data analysis
The whole expression files of SCs and NSCs were assessed with mRNA-Seq experiments performed by Novogene (Beijing, China). The mRNA-seq library is prepared for sequencing according to standard Illumina protocols. To investigate biologic characteristics of genes differently expressed between SCs and NSCs, we performed GSEA assay. The GSEA method is embodied in a freely available software package, together with an initial database of 1,325 biologically defined gene sets and was developed to help with the analysis and interpretation of the long lists of genes produced from high-throughput transcriptomic experiments. 10, 11 We chose the genes that related to metastasis pathway to analysis. The transcriptome sequencing data were uploaded to the GEO database (accession number GSE112038 
Survival analysis of TMED2
The association between TMED2 expression and OS was analyzed with an online database that was established using gene expression data and survival information of breast cancer patients downloaded from the GEO. 15 Currently, breast cancer, 15 ovarian cancer, 16 gastric cancer, 17 and lung cancer 18 databases have been generated. The database contains a collection of clinical data including histology, stage, grade, gender, and smoking history, and treatment groups include surgery, chemotherapy, and radiotherapy. Briefly, TMED2 was entered into the database (http:// kmplot.com/analysis/) to obtain KM survival plots. The requested mRNA expression above or below the median classified the cases into a high expression group and low expression group. These cohorts were compared with a Kaplan-Meier survival plot, and hazard ratio (HR), 95% confidence interval (CI), and log rank P-value was determined and displayed on the web page. A P-value<0.05 was considered statistically significant.
Western blot analysis
Cells and specimens were lysed in freshly prepared protein extraction buffer (78501, Thermo Scientific) containing phosphatase inhibitors for 30 min on ice. Lysates were centrifuged and then collect the supernatant. The protein was applied to a 12% SDS-polyacrylamide gel, and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% low-fat milk in TBST for 60 min and then incubated with the following primary antibodies overnight (4°C): TMED2 (241213, Abcam,1:2000), β-actin (6276, Abcam,1:5000); The corresponding secondary antibodies (1:5000) were added and bands were visualized by enhanced chemiluminescence (PerkinElmer, MA, USA).
Statistical analysis and calculations
Data were expressed as the Mean ± SEM. All data were analyzed using the InStat software (GraphPad, CA, USA), and displayed as mean ± SEM. Unpaired T-test was used for the comparison between two mean values. Significance was defined at ***P<0.001, **P<0.01, *P<0.05.
Results
Solitary 4T1 cells could form two different phenotypes
When 4T1 cells were cultured at an average density of 1 cell per well in 96-well plate, two distinct phenotypes of clones were observed ( Figure 1A ). While one type of clones was sphere-shaped clone and the other was nonsphere-shaped clone. For clarity, we termed the first type sphere clones (SCs) and the second non-sphere clones (NSCs). The cells freshly prepared from 4T1 tumors passaged in vivo (Balb/c mice) could also generate SCs and NSCs ( Figure 1B ). Moreover, SCs and NSCs accounted for about 9.1±1.3% and 90.9±1.3% respectively ( Figure 1B ).
The surface markers of SC and NSC
As SCs showed sphere-shaped morphology, we supposed that SCs may have stem cell-like features. Pece et al 19 used 6 surface markers to distinguish mammary stem cells from others and they revealed that mammary stem cells are both CD44+/EpCAM+ (epithelial marker) and CD49F +/TP63+ (myoepithelial marker). Then we used these 6 markers to characterize SCs and NSCs ( Figure 2A ) and the result showed that the SCs were CD24+CD44+, while NSC clones were CD24+CD44− ( Figure 2A ). Moreover, both SCs and NSCs were TP63 negative and EpCAMC, CD49F positive ( Figure 2A ). Then we can draw the conclusion that SCs may have breast cancer stem cell characteristics, as identified by Pece et al 19 .
The differentiation capability of SC Under 3D culture ( Figure 2B ), SCs formed acinar-like colonies containing tubular-like structures, whereas NSCs did not form such colonies, that means SCs had the ability of differentiation.
Glycolysis and cell growth rate of SC and NSC
NSCs showed a significantly higher glycolysis rate ( Figure 2C ) and generated more lactate ( Figure 2D ) than SCs. Moreover, the L/G ratios (the amount of lactate generated divided by the amount of glucose consumed) for NSCs and SCs were 1.9 and 0.8 ( Figure 2E ), indicating that NSCs waste significantly higher glucose carbon per unit of consuming glucose. Consistently, NSCs proliferated significantly faster than SCs ( Figure 2F ).
SCs showed a markedly higher metastatic ability than NSCs
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To probe the gene expression of SCs and NSCs, we conducted mRNA-seq analysis of SCs and NSCs. The result displayed that there were 6,465 genes differentially expressed between SCs and NSCs. With the assistant of GSEA, we found that there were 100 genes associated with metastasis ( Figure 3H ), among which, 73 and 27 genes were pro-and anti-metastasis, respectively. 44 and 29 pro-metastatic genes were highly expressed in SC and NSC, respectively.
TMED2 generally increased expressed in breast cancer
We used UALCAN (http://ualcan.path.uab.edu/index. html) to check the expression level of the 44 prometastatic genes mentioned above between breast cancer samples and normal mammary tissue. The result reflected that among these genes TMED2 significantly upregulated in breast cancer samples compared to normal mammary samples ( Figure 4A ). Additionally, with the help of Human Protein Atlas (www.proteinatlas.org), we found the protein expression of TMED2 was positively strong in breast cancer specimens compared with normal mammary samples ( Figure 4B and C).We checked the protein expression of TMED2 by western blot and the results displayed that TMED2 expressed higher in breast cancer tissue as well as SC clones ( Figure 4D ). In order to explore the reason for higher TMED2 levels, we examined the copy number and DNA methylation data of breast cancer sample and normal breast tissue. The results showed that there was no significant different copy number and DNA methylation level between breast cancer and normal mammary tissue ( Figure 4E and F) .
High level of TMED2 was a poor prognostic factor in breast cancer
We checked the overall survival of mice injected with SCs and NSCs. The result showed that the overall survival of SC which higher expressed TMED2 was obviously shorter than NSC ( Figure 5A , P=0.0003). Figure 5C and D). The survival curves indicated that the increased expression level of TMED2 was associated with worse outcome in patients with Luminal A, as Figure 5E showed (HR=1.25, 95% CI 1.05-1.48; P-value=0.01). Moreover, overexpressed TMED2 was associated with worse outcome in patients with Luminal B, as Figure 5F showed (HR=1.33, 95% CI 1.1-1.61; P-value=0.0034). The number of triple-negative breast cancer patients was too small to assess.
Prognosis in patients with mRNA expression of the TMED2 and patient clinicopathological characteristics
Patient clinicopathological characteristics included tumor ER status, PR status, positive lymph-node status, grade, and P53-mutation status et al. Increased TMED2 expression was significantly correlated with reduced patient OS in ER-positive breast cancer patients (HR=1.71, 95% CI 1.19-2.45; P-value=0.0032, Figure 5G ). While mRNA expression levels of TMED2 and patients with ER-negative (HR=0.98, 95% CI 0.63-1.55; P-value=0.95, Figure 5H ), PR-positive (HR=0.91, 95% CI 0.64-1.29; P-value=0.61, Figure 5I ), PR-negative (HR=1.6, 95% CI 0.62-4.12; P-value=0.33, Figure 5J ) breast cancer showed no significant prognostic associations.
As Table 1 showed, there was no significant correlation between mRNA-expression levels of TMED2 and histopathological grades of the breast cancers. As shown in Table 2 , expression levels of mRNA for TMED2 had no relationship with lymph-node-positive (HR 1.14, 95% CI B re a s t c a n c e r C a rc in o id C e rv ic a l c a n c e r C o lo re c ta l c a n c e r E n d o m e tr ia l c a n c e r G lio m a H e a d a n d n e c k c a n c e r L iv e r c a n c e r L u n g c a n c e r L y m p h o m a M e la n o m a O v a ri a n c a n c e r P a n c re a ti c c a n c e r P ro s ta te c a n c e r R e n a l c a n c e r S k in c a n c e r S to m a c h c a n c e r T e s ti s c a n c e r T h y ro id c a n c e r U ro th e lia l c a n c e r 
Discussion
Though TMED family had been discovered over twenty years, the function and mechanism of the TMED family still remained unclear. Some studies reported that disrupted expression of TMED proteins resulted in a great number of diseases ranging from cancer to Alzheimer's. 20 Some researches revealed that TMED3 was a tumor suppressor gene implicated in colon cancer, prostate cancer, and hepatocellular carcinoma progression. [21] [22] [23] However, the function of TMED2 in cancer was rarely studied. The oncogenesis of breast cancer is a synthesis of multifarious molecular events. Owing to the low rate for early diagnosis, frequent failures in conventional treatment strategies and drug resistant, the mortality of breast cancer still remains high. 24 Therefore, it is basic and urgent to excavate some cancer-related molecular markers associated with the prognosis of breast cancer.
In our study, we discovered that SCs and NSCs were two different phenotypes of 4T1 cells. SCs corresponded to high metastatic competence, differentiation ability, low growth rate, and low metabolic rate features. Moreover, we got SCs and NSCs from 4T1 cells in normal culture condition with low density which was a new discovery (Figures 1-3) . By performing transcriptome sequencing data analysis and western blot, we found TMED2 expressed higher in SCs (Figures 3H and 4D) . And with the help of some bioinformatics web tools, we observed an increased expression of TMED2 in breast cancer compared to the normal mammary tissues (Figure 4) . In order to explain the reason for TMED2 higher expressed in breast cancer sample, we analyzed the DNA copy number and DNA methylation level of breast cancer and normal breast tissue but did not find any significant difference ( Figure 4E and F). There were many reasons for genes increased expressed in cancers. Such as gene amplification, the DNA copy number and DNA methylation level. [25] [26] [27] [28] [29] [30] Gene overexpression is a very complicated process, which may be caused by many factors. We were current unable to determine the cause of high expression of TMED2 in breast cancer. We also found that the elevated expression of TMED2 in breast cancer resulted in a poor outcome ( Figure 5 ). Based on these results, we believed TMED2 could serve as a potential breast cancer biomarker and a potential cancer treatment target. We also used limiting dilution method to clone human breast cancer cell lines (MDA-MB-231, Bcap37 and MCF7) and other cell lines (A549 and CT26), but we did not observe the phenotype of SCs and NSCs. It is possible that these cells underwent some other changes that were not identified by us.
In summary, to our knowledge, this is the first time to reveal the existence of SCs and NSCs under common cell culture condition and evaluate the association of TMED2 expression with breast cancer prognosis. Our study suggested that increased expression of TMED2 is associated with a poor result of breast cancer.
